Pediatric UTI Guidelines - Comprehensive Review

1. Definition & Classification

2. Epidemiology & Risk Factors

• Prevalence of UTI in febrile infants with no apparent source: ~5%
• Fever >38°C lasting >2 days without identified source: positive likelihood ratio of 3.6 for occult UTI
• Girls are at significantly higher risk than boys after the neonatal period
• Risk factors: female sex, uncircumcised males, VUR, urinary tract anomalies, constipation/bladder-bowel dysfunction

3. Clinical Presentation

• Fever, irritability, poor feeding, vomiting, diarrhea
• Jaundice (especially neonates), failure to thrive, foul-smelling urine

• Dysuria, frequency, urgency
• Enuresis, incontinence, voiding changes
• Suprapubic or flank/abdominal pain

Note: Even with classic symptoms in children 2-19 years, UTI prevalence is only ~7.8% - other diagnoses (bladder-bowel dysfunction, vulvovaginitis) must be considered.

4. Urine Collection Method

5. Urinalysis Interpretation

• Leukocyte esterase (LE): positive
• Nitrites: positive (highly specific but low sensitivity; gram-negative organisms only)
• Pyuria: >5 WBC/hpf (or >10 WBC/mm³ on unspun urine)
• Both LE and nitrites positive = strong predictor

• Catheter specimen: ≥10,000-50,000 CFU/mL of a single pathogen (AAP: >50,000 CFU/mL; some experts accept ≥10,000 CFU/mL with pyuria + fever)
• SPA: any growth is significant
• Clean catch: ≥100,000 CFU/mL

6. When to Send Culture

• All children <3 months suspected of UTI - regardless of UA result (if catheter specimen obtained)
• All children <12 years with urinary symptoms + positive UA (+LE and/or +nitrites)
• All children starting empiric antibiotics for suspected UTI

7. Additional Lab Work-up

• Blood culture: indicated in neonates (<28-30 days), and ill-appearing infants <3 months
• CBC, CRP, procalcitonin: can support pyelonephritis diagnosis but not routinely required
• Serum creatinine: if concern for renal impairment
• Lumbar puncture: consider in neonates and young infants appearing septic

8. Treatment

A. Who Gets Empiric Antibiotics?

• Positive UA (LE and/or nitrites) with compatible symptoms
• Ill-appearing child - start empirically before culture results
• Febrile infant <3 months - treat empirically pending culture

B. Route of Administration

• Oral is first-line for most children - equivalent efficacy to IV for uncomplicated pyelonephritis
• IV/parenteral if: toxic-appearing, persistent vomiting, severe dehydration, unable to tolerate oral medications, neonates

C. Empiric Antibiotic Choices

Amoxicillin alone is not recommended empirically due to high E. coli resistance.

• Ceftriaxone 50-75 mg/kg/day IV q24h
• Gentamicin 5-7.5 mg/kg/dose IV q24h (monitor levels if >48h)
• Transition to oral once afebrile and tolerating PO

D. Treatment Duration (2023 SCOUT Trial Update)

• Cystitis: 3 days is adequate (non-inferior to longer courses per 2023 SCOUT RCT)
• Pyelonephritis/febrile UTI: 7-10 days total (oral or IV-to-oral)
• Neonates: 10-14 days

9. Admission Criteria

• Age <2 months (some centers: <3 months)
• Toxic/septic appearance
• Unable to tolerate oral medications
• Immunocompromised state
• Concern for obstruction or abscess
• Poor social circumstances, inability to follow up

10. Imaging

Renal-Bladder Ultrasound (RBUS)

• Recommended after first febrile UTI in children 2-24 months
• Can be done after infection resolves (not urgently unless abscess/obstruction suspected)
• Recent 2023 meta-analysis (JAMA Pediatrics): 22.1% have urinary tract abnormalities, but only 3.1% are clinically important
• Current evidence suggests limiting RBUS to children with a second febrile UTI may be more cost-effective

VCUG (Voiding Cystourethrogram)

• NOT routine after first febrile UTI
• Indicated if:
  • Second febrile UTI
  • RBUS shows hydronephrosis, renal scarring, or parenchymal abnormality
  • Abnormal prenatal ultrasound
  • Non-E. coli organism, atypical course

DMSA Scan (Dimercaptosuccinic Acid)

• Detects acute pyelonephritis and renal scarring
• "Top-down approach": DMSA first, then VCUG only if DMSA abnormal
• NICE guidelines: DMSA 4-6 months post-infection for:
  • Children <3 years with atypical or recurrent UTI
  • Children >3 years with recurrent UTI
• AAP: does not recommend routine DMSA

11. Antibiotic Prophylaxis

• Not routinely recommended after first febrile UTI
• Consider in VUR grade IV-V or higher
• Evidence supports prophylaxis in children with bladder-bowel dysfunction and recurrent UTIs
• 2024 systematic review (PMID 39492618): prophylaxis options remain debated for recurrent UTI

12. Special Populations

13. Follow-Up

• Clinical reassessment at 48-72 hours if empiric therapy started
• If no improvement in 48 hours: repeat culture, consider imaging, broaden coverage
• After 7 days of therapy: close clinical monitoring for recurrence
• Screen all toilet-trained children for bladder-bowel dysfunction

Recent Guideline Updates (2024)

• WikiGuidelines 2024 (JAMA Netw Open, PMID 39495518): Multinational consensus found most UTI recommendations lack high-quality prospective data; only 6 of 37 questions had clear evidence-based recommendations.
• ACR Appropriateness Criteria 2023 (PMID 38823954): Updated imaging guidance - RBUS remains appropriate for first febrile UTI; VCUG not routine after first uncomplicated UTI.
• SCOUT Trial 2023 (JAMA Pediatrics): Short-course therapy (3-day) non-inferior to longer courses for uncomplicated childhood UTIs.